Oryzon Genomics S.A. (ORYZF) Financials

ORYZF Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 186.7 million 30.8 million
Dec. 31, 2025 169.6 million 31.3 million
Sept. 30, 2025 171.3 million 34.1 million
June 30, 2025 163.1 million 28.4 million

ORYZF Free Cash Flow and Stock based compensation

No data available :(

ORYZF Net Income

No data available :(

ORYZF Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 - - -
Dec. 31, 2025 33.3 million 7.9 million 12282
Sept. 30, 2025 40.5 million 4.8 million 19467
June 30, 2025 36.7 million 5.9 million 54061

ORYZF Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 88.8 million
Dec. 31, 2025 91.0 million
Sept. 30, 2025 88.2 million
June 30, 2025 91.4 million

ORYZF Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 - 5.1 million 1.5 million -
Dec. 31, 2025 - 5.2 million -2.9 million -
Sept. 30, 2025 - 3.9 million 1.2 million -
June 30, 2025 - 1.1 million 1.7 million 536419

ORYZF Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 - -
Dec. 31, 2025 - 37022
Sept. 30, 2025 - 37988
June 30, 2025 5.0 million 173553

ORYZF

Price: $3.66

52 week price:
3.03
4.38

Earnings Per Share: -0.03 USD

Exchange: PNK

Sector: Healthcare

Industry: Biotechnology

Market Capitalization: 283.3 million

Links: